CAR T Therapy: Successes and Risks in Multiple Myeloma

Описание: In this Clinic Conversation of the Week, Rahul Banerjee, MD, FACP, Assistant Professor of Medicine at Fred Hutchinson Cancer Center, discusses second primary malignancies and T-cell lymphoma risks following CAR T-cell therapy in multiple myeloma. Highlighting a recent case report from the New England Journal of Medicine, Dr. Banerjee explains how CAR T therapy can lead to rare but documented malignancies due to genetic integration.

Dr. Banerjee explores how to approach this complex topic with patients, balancing the life-saving benefits of CAR T therapy with its risks. He also discusses alternative treatments like bispecific antibodies and the potential of allogeneic CAR T-cell products to mitigate these risks. This conversation underscores the importance of patient-centered communication and continued research in the evolving field of immunotherapy.

Watch now to learn how to navigate these critical discussions with patients and stay informed about the latest advancements in CAR T therapy.

#CARTTherapy #MultipleMyeloma #Immunotherapy #CancerTreatment #TCellLymphoma #Oncology #PatientCare #CancerResearch #Hematology #CARTRisks